Le Lézard
Classified in: Business
Subject: STH

IIROC Trading Halt - ECC


VANCOUVER, Aug. 1, 2018 /CNW/ - The following issues have been halted by IIROC:

Company: Ethos Gold Corp.

TSX-Venture Symbol: ECC

Reason: At the Request of the Company Pending News

Halt Time (ET): 10:22 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions


These press releases may also interest you

at 16:25
Xylem Inc. , a leading global water technology company dedicated to solving the world's most challenging water issues, will release its first quarter 2024 results at 6:55 a.m. (ET) on Thursday, May 2, 2024. At 9:00 a.m. (ET), Xylem's senior...

at 16:25
Amerant Bancorp Inc. ("Amerant" or the "Company"), today announced it will release first quarter 2024 earnings results on Wednesday, April 24, 2024 after the market closes. Once released, investors may access Amerant's earnings results at...

at 16:25
Fortive Corporation ("Fortive") today announced that it will webcast its earnings conference call for the first quarter 2024 on Wednesday, April 24, 2024 beginning at 12:00 p.m. ET and lasting approximately 1 hour. The call and an accompanying...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
Intellinetics, Inc. , a digital transformation solutions provider, announced financial results for the three and 12 months ended December 31, 2023. 2023 Fourth Quarter Financial Highlights Total Revenue increased 3.8% over the same period in...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...



News published on and distributed by: